Robotic Gait Rehabilitation in Parkinson's Disease

Parkinson Disease Clinical Trial

Official title:

Robotic Gait Rehabilitation in Parkinson's Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05218187
• Other study ID #: 11829
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: January 10, 2022
• Est. completion date: December 2025

Study information

• Verified date: April 2024
• Source: Indiana University
• Contact: Peter Altenburger, PhD
• Phone: 3172780703
• Email: paltenbu[@]iu.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate the implementation of a novel gait rehabilitation stimulus (G-EO System) that could advance current clinical practices. The goal is to establish the safety and feasibility of gait training using the G-EO System as well as investigating the impact on mobility, function, quality of life, and participatory outcomes.

Research Design: We propose a single-blinded, randomized trial of electromechanically-assisted gait training using the G-EO System in patients with Parkinson's disease with gait disability.

Specific Aim 1 will establish the safety and feasibility of gait training using the G-EO System.

Specific Aim 2 will determine the efficacy of gait training using the G-EO System for improving mobility, function, and quality of life

Description:

Individuals diagnosed with Parkinson's disease (PD) often suffer from difficulties with gait initiation, maintaining a consistent kinematic gait pattern, and transitions between gait environments. Focused gait training that provides an environment that can emphasize motor control improvement in these deficits would be ideal for building a rehabilitative foundation for gait recovery for individuals with PD.

One approach that has been used to maintain and restore function in other neurological populations with severe disability is gait rehabilitation using treadmill training. This approach allows for specific and repetitive practice of walking movement and can involve therapist or electromechanical assistance. There is preliminary evidence from two small, uncontrolled studies supporting the benefits of therapist-assisted treadmill training on walking, balance, fatigue, spasticity, muscle strength, and quality of life in patients with PPMS and SPMS. Nevertheless, therapist-assisted gait training can require up to three trainers per patient making it burdensome and inefficient in the clinical setting. The intensity of manual treadmill training is low (i.e., <1.5 METs) based in part on the physical capacity and fitness level of the trainers, yet physiological adaptations for optimizing outcomes require moderate or vigorous intensity exercise.

Robotic-assisted gait training (RAGT) addresses many of the limitations of therapist-assisted gait training and can be performed using either exoskeleton or end-effector devices. Exoskeleton devices involve programmable drives or passive elements which physically move the lower limbs, whereas, end-effector approaches involve driven footplates that have trajectories that simulate the stance and swing phases. The G-EO System (Reha Technology AG: Olten, Switzerland) is a novel end-effector robotic gait training system that was developed for regaining mobility and independence in stroke survivors. This system involves minimal therapist and patient burden (e.g., quick set-up, single operate usage), there is the unique capacity for practicing walking and stair climbing movements, and the patient can receive real-time visual feedback. Gait training using the G-EO System has been applied in patients with stroke, Multiple Sclerosis (MS), and cerebral palsy (CP). These studies have established safety and feasibility, and preliminary evidence for benefits on mobility and function. For example, two studies involving 4 weeks of G-EO training with conventional physical therapy in non-ambulatory subacute stroke patients reported improved gait, stair climbing ability, leg strength, and activities of daily living (ADL) compared to physical therapy alone. There is limited RAGT studies evaluating the impact of this type of training for individuals with PD. The potential focus on improved gait kinematics may be of particular benefit for PD patients who often struggle with maintain step length and initiation.

The logistic advantages and advanced training capabilities of the G-EO System, as well as the benefits reported in other populations, support this strategy as an effective rehabilitation tool for restoring and maintaining function in Parkinson's disease. This approach represents an opportunity for improving current clinical practices for patients with Parkinson's disease. If successful, this project will provide initial evidence for increasing patient access to the G-EO System, and this could be accomplished through "regional technology centers" using a rural health-delivery approach.

The purpose of this study is to investigate the implementation of a novel gait rehabilitation stimulus (G-EO System) that could advance current clinical practices. The goal is to establish the safety and feasibility of gait training using the G-EO System as well as investigating the impact on mobility, function, quality of life, and participatory outcomes.

Research Design: We propose a single-blinded, randomized trial of electromechanically-assisted gait training using the G-EO System in patients with Parkinson's disease with gait disability.

Specific Aim 1 will establish the safety and feasibility of gait training using the G-EO System.

Specific Aim 2 will determine the efficacy of gait training using the G-EO System for improving mobility, function, and quality of life.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 2025
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age > 18years

• Confirmed diagnosis of Parkinson's Disease

• Hoehn and Yahr stage 1 to 3

• Stable course of disease-modifying therapy over the past 3 months

• Mini Mental State Examination > 24

• Physician approval for exercise

• Stable deep brain stimulation setting for the past year

• Demonstrate a need for functional rehabilitation

Exclusion Criteria:

• • Severe dyskinesia or severe on-off phenomenon

• Unstable medication regiment

• Any co-morbidity that will interfere with walking

• Conventional physical therapy or G-EO training within the past 6 months

• Height <1m or >2m

• Body weight >150 kg

• Contraindications to G-EO gait training (e.g., bone instability)

Related Conditions & MeSH terms

• Gait Disorder, Sensorimotor
• Gait Disorders, Neurologic
• Parkinson Disease

Intervention

Device:
• G-EO End-Effector Gait Trainer
The G-EO Gait Trainer uses distal fixation to promote a gait recovery by facilitating a controlled walking environment that includes an over-ground pattern and stair climbing. In addition, the device provides body position control to enable the patient to concentrate on the cyclical motion of walking without the fear of falling. Physical therapists can control different parameters of the gait cycle through computerized adjustments and the training setting can be manipulated to engage patients in active participation.

Other:
• Conventional Physical Therapy Treatment
Therapists will use traditional methods of neurological rehabilitation for improved gait and balance. These approaches will include stretching, strengthening, therapeutic exercises, balance training, and over-ground walking

Locations

Country	Name	City	State
United States	IU Health Neurorehabilitation and Robotics	Indianapolis	Indiana

Sponsors (1)

Lead Sponsor	Collaborator
Indiana University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Comfortable Walking Speed (CWS)	Participants will be asked to walk over a 14-foot pressure mat that will capture their comfortable walking speed. Patients will be instructed to walk at their normal comfortable speed. Walking will begin 5 feet prior to the mat so that each individual walks across the mat at a consistent speed. Participants will pass over the mat 2 times and an average speed will be calculated.	It will take 5 minutes to complete this test and will be performed first
Primary	Fast Walking Speed (FWS)	Participants will be asked to walk over a 14-foot pressure mat that will capture their fast walking speed. Patients will be instructed to walk at their fastest speed while maintaining safe, accurate gait. Walking will begin 5 feet prior to the mat so that each individual walks across the mat at a consistent speed. Participants will pass over the mat 2 times and an average speed will be calculated.	It will take 5 minutes to complete this test and will be performed second
Primary	Six Minute Walk Test (6MWT)	Participants will be asked to walk for 6 minutes along a 30m track that is a flat surface and obstacle free. Subjects may stop and rest as often as needed. Researchers will record the distance traveled during the six minute time period.	It will take 10 minutes to complete this test and will be performed third
Secondary	Six Minute Walk Test Walking Speed (6MWT)	Participants will be asked to walk for 6 minutes along a 30m track that is a flat surface and obstacle free. Subjects may stop and rest as often as needed. Researchers will record the change in walking speed to calculate the rate of functional fatigue while walking.	It will take 10 minutes to complete this test. The speed metrics will be recorded while the primary 6MWT data is being captured.
Secondary	Mini BESTest	Subjects will be asked to complete 14 different balance related tasks ranging from static standing to dynamic walking. The tasks target 4 different balance control systems. This is a shortened version of the Balance Evaluation Systems Test (BESTest). All subjects will be guarded closely for safety to prevent falling.	The test takes about 15 minutes to administer
Secondary	The Five Times Sit to Stand Test	The test will quantify functional lower extremity strength. It provides insight into the coordination of functional strength for the accomplishment of transitioning from one posture to another. The participant is asked to safely rise from sitting in a chair to standing and then sit back down five times in a row without using their hands.	This test will take about 5 minutes to administer
Secondary	Activities-Specific Balance Confidence Scale (ABC)	Self-report measure of balance confidence as measured by the patient's perception of their ability to perform various activities without losing their balance. There are sixteen items that the participant score on a zero to 100 percent scale.	This survey will take about 10 minutes to complete
Secondary	Parkinson's disease Questionnaire-39 (PDQ39)	This is a 39 Item self-report questionnaire that evaluates Parkinson's disease specific health related quality of life over the past month. The questions are categorized into 8 different dimensions of quality of life. The outcomes will illustrate how Parkinson's disease is impacting their well-being and overall functioning.	The survey will take about 20 minutes to complete